Prevalence of neuropathic pain in patients with cancer

Abstract

BACKGROUND AND OBJECTIVES: To evaluate the prevalence and factors associated with neuropathic pain in cancer patients METHODS: A prospective cross-sectional study conducted from August 2016 to July 2017, with 267 cancer patients above 18 years of age, with pain. Diabetic patients and patients with previous chronic pain unrelated to the current neoplasia were excluded. The demographic and disease information was obtained from the medical records and directly with the patient. The Douleur Neuropathique en 4 questions questionnaire and the numeric pain scale were later applied. RESULTS: The prevalence of neuropathic pain in the study population was 53%. The average age of patients was 55.3 years. Of the 267 patients, 76% were female. There was no significant difference in the occurrence of neuropathic pain among gender, age, histological type of cancer and type of treatment. Of the patients, 35.5% who underwent chemotherapy had neuropathic pain, and there was no statistical difference between the types of chemotherapy performed. Twenty-four patients who reported pain at the radiotherapy site were diagnosed with neuropathic pain. Of the total, 63 patients who reported pain at the surgical site, 36 were classified with neuropathic pain. An increasing trend of neuropathic pain was observed when treatments were associated. The intensity of this pain was reported as moderate to severe by the majority of patients in the various types of treatment: chemotherapy, radiotherapy, and surgery. CONCLUSION: When compared to other studies, a high prevalence of neuropathic pain was observed in more than half of the patients evaluated.

Índice De Dor Neuropática Em Pacientes Oncológicos E Conduta Farmacológica

“…Além disso, estes pacientes que se mostraram positivos para DN equivalem aos pacientes classificados com dores fortes que não atingem analgesia adequada. Um dado importante encontrado no artigo de Couceiro, et al (2018), consiste na relação aos pacientes que realizaram um grande número de intervenções e apresentaram proporções significativas de sintomas característicos de DN, e esse resultado denota que casos avançados de câncer com muitas tentativas de tratamento pode aumentar o risco para o seu desenvolvimento.…”

“…Com relação à radioterapia, essa intervenção promove lesão neuronal devido aos processos inflamatórios e fibrogênicos, acrescidos de alterações vasculares que propiciam isquemia. Ademais, a DN pode resultar da invasão direta nas fibras nervosas pelo tumor (COUCEIRO, et al, 2018;FERRONATTO et al, 2020).…”

“…O câncer em si, somado a muitos dos tratamentos utilizados rotineiramente podem levar à dor neuropática (WIERMANN, et al, 2014). Cerca de metade dos pacientes com dor relacionada ao câncer podem referir dor neuropática, especialmente influenciado pela dose, pelo efeito cumulativo e pela classe do agente quimioterápico empregado, principalmente quando o quimioterápico é da classe dos alcaloides, taxanos e derivados da platina (COUCEIRO, et al, 2018). É sempre desejável que a patologia subjacente à dor neuropática seja identificada, e tratamento específico seja recomendado; as doses dos analgésicos devem ser tituladas com base na eficácia e no aparecimento de eventos adversos (WIERMANN, et al, 2014).…”

“…Com isso, ressalta-se a existência de diferentes medidas para alívio da dor oncológica, sejam farmacológicas ou outras terapias que promovam o bem-estar físico e psicológico do paciente. Sendo assim, profissional deve estimular o paciente a falar da dor nas suas diversas formas, interferindo adequadamente para melhorar a sua qualidade de vida (COUCEIRO, et al, 2018). Neste sentido, o presente estudo teve por objetivo avaliar a prevalência de dor neuropática nos pacientes atendidos pelo grupo interdisciplinar de atendimento paliativo (GIAP) no Hospital de Câncer de Cascavel UOPECCAN.…”

Prevalensi Nyeri Neuropatik Pada Pasien Dengan Nyeri Kanker Di Rsupn DR Cipto Mangunkusumo Dan PKN Rs Dharmais

“…Dalam penelitian ini ditemukan sebagian besar subjek (64,9%) adalah perempuan, mirip dengan Couceiro dkk bahwa mayoritas pasien yang mengalami nyeri kanker adalah perempuan (75,6%). 8 Hal ini dimungkinkan karena jenis kanker terbanyak dalam penelitian ini kanker payudara (38,6%) yang Usia rerata subjek dalam penelitian ini adalah 45,91+12,41 tahun, jauh lebih muda dibandingkan dengan penelitian Reis-Pina dkk (62,1 tahun) dan Couceiro dkk (55,3 tahun). [8][9] Namun, telaah sistematis oleh Roberto dkk menyatakan median umur pada pasien dengan nyeri kanker neuropatik adalah 48 tahun.…”